ResMed Inc. reported a strong financial performance for the fiscal year ending June 30, 2026, with net revenues reaching $5.65 billion, a 10% increase from $5.15 billion in the previous fiscal year. The company's gross profit also rose to $3.45 billion, reflecting a 13% increase compared to $3.06 billion in fiscal 2025. Net income for the year was $1.52 billion, or $10.43 per diluted share, up from $1.40 billion, or $9.51 per diluted share, in the prior year. This growth was attributed to increased demand for its sleep and breathing health products, particularly devices and masks, which saw revenue increases of 9% and 13%, respectively.
The company experienced significant operational changes, including the acquisition of Noctrix Health, LLC, a company specializing in wearable therapeutics for restless legs syndrome, for $335 million. This acquisition is expected to enhance ResMed's clinical sleep health portfolio. Additionally, ResMed announced the planned divestiture of its MatrixCare business for $490 million, a move aimed at optimizing its focus on core growth areas in sleep and breathing health. The MatrixCare business generated approximately $220 million in revenue during fiscal 2026.
In terms of operational metrics, ResMed employed approximately 11,370 people and sold products in over 140 countries. The company reported a total of 35 million patients using its cloud-connected devices, with over 12 million registered on its myAir platform, which supports patient engagement and therapy adherence. The company’s residential care software solutions supported over 180 million individual patient accounts, indicating a strong market presence.
Looking ahead, ResMed anticipates continued growth driven by increasing awareness of sleep apnea and chronic obstructive pulmonary disease (COPD), alongside ongoing investments in research and development, which totaled $378 million in fiscal 2026. The company aims to leverage its digital health ecosystem to enhance patient outcomes and operational efficiencies. However, it also faces challenges, including potential impacts from healthcare reforms, supply chain disruptions, and competitive pressures in the medical device market.
About RESMED INC
ResMed Inc. specializes in digital health and cloud-connected medical devices for sleep and respiratory care. Its core offerings include CPAP, ventilators, diagnostic tools, and software solutions for sleep apnea, COPD, and other chronic respiratory diseases. Serving global markets, the company focuses on improving patient outcomes, enhancing therapy adherence, and streamlining care delivery through innovative products, connected care platforms, and residential care software.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov